• by admin1
  • September 7 2013


Healthcare Reform Should Help IVD Industry, At Least Slightly

On the whole, Patient Protection and Affordable Care Act is expected to benefit the IVD and clinical lab test industry slightly, according to Kalorama Information. Sales are expected to rise an extra 1.3% more per year, in the next five years, than would have otherwise been seen without the law, according to a recent report from the firm. This finding was made in a recently published Kalorama Information report, The Impact of Healthcare Reform (PPACA) On the U.S. IVD Market.

The healthcare mar...

  • by admin1
  • September 7 2013


AACC Meeting Provides Industry Glance

The very size of the American Association of Clinical Chemistry is a testament to the growth of the IVD industry that Kalorama has covered for decades. This year’s AACC in Houston, TX did not disappoint. 650 companies exhibited, 100 of them were new.

Key areas of interest were emerging markets for IVD, Vitamin D’s continued role in the face of controversy, and the recent Supreme Court ruling that isolated human DNA cannot be patented. AACC hosted a panel featuring ACLU Lead Counsel Sandra Park...

  • by admin1
  • September 7 2013


Proof of RPM Benefit Emerges

Proof of RPM Benefit Emerges

The proof of the pudding is in the eating, or so the saying goes. For insurance companies and governments, they will reimburse if the product can show effectiveness. As detailed in our report on Advanced Remote Patient Monitoring (http://www.kaloramainformation.com/Advanced-Remote-Patient-7450566/) These developments will drive implementation of new systems.

Numerous studies in the United States and Europe have proven the cost benefits of remote patient monitoring (RPM), despite initial costs ...

  • by admin1
  • September 7 2013


Cancer Testing Opportunity in Developing Nations

As cancer diagnostics prove to be the key to early detection and improved cancer outcomes, developing nations will be an increasingly important market for these products, says Kalorama Information. The healthcare market research publisher said that 80% of the market for cancer testing products is now in developed nations, but there is opportunity in the remaining market. The healthcare market research publisher says western nations have the highest incidence, but also the highest survival rates ...